iBio Inc

ibioinc.com

What Do They Do?

Develops AI-designed antibody drug candidates for obesity and related cardiometabolic and cardiopulmonary diseases.

How Do They Make Money?

For fixed-fee work, iBio charges an agreed amount for a deliverable, typically receiving payment after the project is finished and delivered. Research collaborations may also bring payments tied to development progress and reimbursements for research costs.

FY2026 revenue

Do Revenues Turn Into Profits?

No. It lost $33M in FY2026.

Operating income, FY2026

−35141% of revenue

▲ +89% (Loss) vs FY2025 (−$18.6M, −4651%)

Net income, FY2026

−33000% of revenue

▲ +80% (Loss) vs FY2025 (−$18.4M, −4594%)

Free cash flow, FY2026

−23778% of revenue

▲ +55% (Loss) vs FY2025 (−$15.3M, −3829%)

How Are They Changing?

Shrinking. Revenue fell 95% in 4 years, from $1.9M in FY2022 to $100K in FY2026, about 52% a year.

Therapeutic focus Where the older report focused internal development on oncology, the current strategy centers on obesity and related cardiometabolic and cardiopulmonary diseases.

Who Do They Compete With?

Competes with Eli Lilly, Novo Nordisk, Amgen, Bristol-Myers Squibb, Merck &, Novartis, AstraZeneca, Johnson & Johnson, Pfizer, Merck KGaA, Sanofi, Roche, Regeneron, Keros Therapeutics, Scholar Rock, Biohaven, Basecure Therapeutics, Structure Therapeutics, Viking Therapeutics, and Veru

Comments